Contrasting RadNet (NASDAQ:RDNT) and Daxor (NASDAQ:DXR)

Daxor (NASDAQ:DXR) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Analyst Ratings

This is a summary of recent recommendations for Daxor and RadNet, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0	1	2	0	2.67
RadNet	1	1	5	2	2.89

Daxor currently has a consensus target price of $25.00, suggesting a potential upside of 104.75%. RadNet has a consensus target price of $90.33, suggesting a potential upside of 28.90%. Given Daxor’s higher probable upside, equities analysts plainly believe Daxor is more favorable than RadNet.

Institutional and Insider Ownership

1.3% of Daxor shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 59.5% of Daxor shares are held by insiders. Comparatively, 5.6% of RadNet shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Daxor has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, RadNet has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.

Profitability

This table compares Daxor and RadNet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
RadNet	-0.65%	2.52%	0.87%

Valuation & Earnings

This table compares Daxor and RadNet”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	$3.31 million	18.58	N/A	N/A	N/A
RadNet	$1.83 billion	2.96	$2.79 million	($0.17)	-412.24

RadNet has higher revenue and earnings than Daxor.

Summary

RadNet beats Daxor on 8 of the 12 factors compared between the two stocks.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

About RadNet

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.